ATC
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors (NCT05668585) | C4 Therapeutics, Inc. | 2022-12-08 |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation (NCT05102292) | Shanghai Henlius Biotech | 2021-12-10 |
Track ATC automatically
Every clearance here is in the API, with alerts when new ones post.